CFO Anthony Doyle resigns at Biocryst

Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) disclosed the resignation of CFO Anthony Doyle, effective April 9, after five years in the role. The company is searching for a replacement. Doyle held the position when Biocryst received approval in late 2020 of Orladeyo berotralstrat as prophylaxis for attacks of hereditary angioedema; its sales rose 34% to $437.7 million in 2024. 

Co-founder Mark DePristo has stepped down as CEO of Bighat Biosciences Inc. and is succeeded by fellow co-founder Peyton Greenside, who was president and CSO. Bighat, which has a machine learning platform for discovering antibodies, has partnered with at least four pharmas, and is planning its first clinical trial in 2026.  ...